Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

MannKind

Cassava Sciences Inc

Biotech stocks have gotten caught up in the broader technology sector sell-off. The benchmark iShares Biotechnology ETF (NYSEARCA: IBB ) has fallen from a peak of $175 in 2021 to just $130 today.

3 Biotech Stocks to Avoid Like the Plague

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression —

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

Amarin Corporation plc (NASDAQ:AMRN ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Aaron Berg - Interim President & Chief Executive Officer Tom Reilly - Chief Financial Officer Steve Ketchum - President R&D and Chief Scientific Officer Conference Call Participants Louise Chen - Cantor Roanna Ruiz - SVB Securities Operator Greetings and welcome to Amarin Corporation's Conference Call to Discuss its First Quarter 2023 Financial Results and Operational Update. I would now like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at Amarin.

Amarin Corporation plc (AMRN) Q1 2023 Earnings Call Transcript

-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing --

Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

Corcept Therapeutics

Ionis Pharma

Pacira Pharmaceuticals

United Therapeutics

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin's senior management team to discuss the Company's first quarter 2023 financial results on Wednesday, May 3rd, 2023 at 8:00 a.m. ET.

Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer (CEO). In addition, the board has appointed Oliver O'Connor as a new independent Director of the company. Both appointments are effective immediately.

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O'Connor to Company's Board of Directors

Sarissa Capital has taken full control of Amarin. The previous management was doing some slow but decent work, but did not get time to show results.

Amarin: Sarissa Has Control, But Amarin Will Need Patience

Agenus

Axsome Therapeutics

Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.

Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today

-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –-

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

Shares of Amarin Corp. AMRN, -5.19% rose dropped 5.5% toward a near three-month low in premarket trading Friday, after the biopharmaceutical company focused on therapies for cardiovascular health disclosed that Chief Executive Karim Mikhail has resigned, effective immediately, after about 19 months in the role. “Mr. Mikhail has asserted that he is entitled to severance payments as the result of his resignation, which the company disagrees with and intends to dispute,” Amarin said in a statement.

Amarin stock falls after CEO Mikhail resigns, company disputes CEO asserting of entitlement to severance

New Amarin Board Believes the Company Will Thrive with Proper Stewardship

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

Amarin Corporation plc (NASDAQ:AMRN ) Cowen 43rd Annual Healthcare Conference March 8, 2023 1:30 PM ET Company Participants Karim Mikhail - President and CEO Conference Call Participants Georgi Yordanov - Cowen and Company Georgi Yordanov Oh, we're very happy to have Amarin today for a fireside chat. And we're sitting here with the CEO of Amarin.

Amarin Corporation plc (AMRN) Cowen 43rd Annual Healthcare Conference (Transcript)

DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to avoid further proxy contests, all seven independent non-Sarissa board members: Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Dr. Murray Stewart, Jan van Heek and Alfonso “Chito” Zulueta will resign from the Board of Directors, effective immediately.

Amarin Announces Board Departures

--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -–

Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

--Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding-- --Analysis Builds on Consistently Demonstrated Positive Outcomes for VASCEPA/VAZKEPA Across Sub-Populations in REDUCE-IT, Including in Patients with Prior Myocardial Infarction (MI), Prior Revascularization, Prior Peripheral Arterial Disease (PAD) and Diabetes--

Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.

Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates

Cidara Therapeutics

iBio

Sidus Space

Vascular Biogenics

Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 5 To Watch Before Next Week

Amarin Corporation plc (NASDAQ:AMRN ) Q4 2022 Results Conference Call March 1, 2023 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants Roanna Ruiz - SVB Leerink Louise Chen - Cantor Cade Cruz - Goldman Sachs Naresh Chouhan - Intron Health Operator Welcome to Amarin Corporation's Conference Call to Discuss its Fourth Quarter and Full Year 2022 Financial Results and Operational Update. I would now like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at Amarin.

Amarin Corporation plc (AMRN) Q4 2022 Earnings Call Transcript

-- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Announced Cost Savings Program On-Track to Exceed $100 Million Target --

Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Positive cash flow in the U.S. for the 3rd quarter. European launch of VASCEPA began in the 4th quarter.

Positive Events Are Lining Up At Amarin

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa.

Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide

DUBLIN, Ireland and BRIDGEWATER. N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, based on the preliminary voting results provided by its proxy solicitors following the Company's 2023 General Meeting of Shareholders (the “General Meeting”), Amarin shareholders have voted to elect all seven of Sarissa's nominees and remove Per Wold-Olsen as Chairman of the Board of Directors, effective immediately.

Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders

DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.

News for Amarin Corporation Plc Stock (AMRN)